TelyRx Launches New Brand and Digital Experience Inspired by Patient Feedback
Clearwater, Florida--(Newsfile Corp. - August 4, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF), a technology-enabled healthcare and digital pharmacy platform, today announced the launch of its new brand platform and digital experience, designed around the needs of modern patients. Shaped by insights gathered from patients over the past two years, the launch represents a significant investment in building a healthcare bra
Healthcare and Hospitals, Health
2026-08-04 7:30 AM EDT | TelyRx
Rise Nano Optics Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) ("Rise" or the "Company") a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's common shares are also now DTC eligible, enhancing the accessibilit
2026-08-04 7:00 AM EDT | Rise Nano Optics Ltd.
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat P
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-04 7:00 AM EDT | Elite Pharmaceuticals, Inc.
TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a strategic partnership with Stealth Health (stealth.health), a leading telemedicine platform for longevity and precision wellness in North America. The agreement integrates TempraMed's VIVI product portfolio into
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-04 7:00 AM EDT | TempraMed Technologies Ltd.
WELL Health Strengthens Executive Leadership Team with Appointments of Loreto Grimaldi as Chief Legal Officer and Kaytek Przybylski as Chief Digital & Information Officer
WELL appoints accomplished legal and business executive Loreto Grimaldi as Chief Legal Officer to lead legal, compliance, governance, risk management and M&A activities across the organization. Seasoned technology and digital transformation leader Kaytek Przybylski joins WELL as Chief Digital & Information Officer to lead enterprise technology, digital transformation, data, AI, and cybersecurity and technology shared services strategy.
Technology, Computer Software, Healthcare and Hospitals, Health
2026-08-04 6:30 AM EDT | WELL Health Technologies Corp.
Edison Group Reaches Global Audience of over 8.5 Million
London, United Kingdom--(Newsfile Corp. - August 4, 2026) - Edison Group, the leading global investor relations and research firm, today announced a major milestone: over the past 12 months, its content generated more than 8.5m investor engagements, views and reads from investors across all pools of capital, in every financial centre and beyond.
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-08-04 6:02 AM EDT | Edison Group
WELL Health to Announce Second Quarter 2026 Financial Results on August 6, 2026
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursd
Technology, Computer Software, Healthcare and Hospitals, Health
2026-08-04 6:00 AM EDT | WELL Health Technologies Corp.
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026. As part of the leadership transitio
Biotechnology, Pharmaceuticals, Health
2026-08-04 3:15 AM EDT | Defence Therapeutics Inc.
Verisante Technology, Inc. Announces Resignation of Director
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2026) - Verisante Technology, Inc. (TSXV: VER.H) ("Verisante" or the "Company") announces that Dr. Jake Thiessen, PhD has resigned as a director of the Company effective August 3, 2026. "On behalf of the Board of Directors, I want to sincerely thank Dr. Thiessen for his dedication and contributions to Verisante," said Thomas Braun, Chief Executive Officer. The Company confirms that there are no matters referred to in
2026-08-03 11:51 PM EDT | Verisante Technology Inc.
WELL Health Subsidiary WELLSTAR Closes C$50 Million Financing Transaction Ahead of Planned TSXV Listing
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR"), has closed a financing transaction for aggregate gross proceeds of C$50 million (the "Financing
Technology, Computer Software, Healthcare and Hospitals, Health
2026-07-31 8:17 AM EDT | WELL Health Technologies Corp.
Jack Nathan Medical Corp. Announces Board Changes and Corporate Update
Toronto, Ontario--(Newsfile Corp. - July 31, 2026) - Jack Nathan Medical Corp. (TSXV: JNH) (OTC Pink: JNHMF) ("Jack Nathan" or the "Company") announces that Blake Lyon, Chairman of the Board of Directors, and Anthony DeCristofaro, Director, have resigned from the Board of Directors of the Company (the "Board"), effective July 31, 2026. Mr. Lyon and Mr. DeCristofaro have each served the Company for many years and have contributed significant time, leadership and experience throughout the
Healthcare and Hospitals, Retail, Health
2026-07-31 6:00 AM EDT | Jack Nathan Medical Corp.
Edison Issues Report on Kooth (KOO)
London, United Kingdom--(Newsfile Corp. - July 31, 2026) - Edison issues report on Kooth (AIM: KOO) Kooth provides clinically accredited digital mental health support, focused on children and young adults. H126 trading was in line with expectations. Adjusted EBITDA is expected to rise to £5.0-5.4m (H125: £1.6m), implying a c 17% margin (H125: 5%) as strong California user engagement compares with a prior year that included accelerated investment. Revenue is expected to be
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-07-31 5:18 AM EDT | Edison Group
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$322,250 under the second tranche through the issuance of 6,445,000 units ("Units") at a price of CDN$0.05
Biotechnology, Pharmaceuticals, Health
2026-07-30 5:57 PM EDT | Hemostemix Inc.
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-07-30 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Edison Issues Report on Trade Estates REIC (TRESTATES)
London, United Kingdom--(Newsfile Corp. - July 30, 2026) - Edison issues report on Trade Estates REIC (ATSE: TRESTATES). Trade Estates REIC (TRESTATES) offers focused exposure to modern retail parks and new-generation logistics assets in Greece, Cyprus and Bulgaria. Demand for both sectors is driven by structural growth trends in retail spending, and both sectors are undersupplied. In Greece, Trade Estates is dominant in modern retail parks, where active management and deep sector exper
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-07-30 11:21 AM EDT | Edison Group
Edison Issues Report on Fourlis Holdings (FOYRK)
London, United Kingdom--(Newsfile Corp. - July 30, 2026) - Edison issues report on Fourlis Holdings (ATSE: FOYRK). Fourlis Holdings is a leading Southeast European retailer operating exclusive long-term franchise and licence agreements with brands such as IKEA, INTERSPORT and Foot Locker, combining their global brand strength with the group's deep local market expertise. The partnerships provide exposure to product categories with favourable growth profiles, including home furnishings,
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-07-30 10:29 AM EDT | Edison Group
Therma Bright Inc. Completes Debt Settlements
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that further to its press release of June 23, 2026, it has now issued an aggregate of 6,613,999 common shares at a deemed price of $0.06 per share to settle aggregate debt of $396,840. All shares issued in relation to these debt settlements a
Technology, Biotechnology, Health
2026-07-30 8:16 AM EDT | Therma Bright Inc.
Delota Reports Financial Results for the Year Ended March 31, 2026
Highlights: Total revenue of $34.8 million for the Year Ended 2026 Total System-Wide Revenue of $39.8 million for the Year Ended 2026 33% gross profit margin for the Year Ended 2026 Segmented revenue for the Year Ended 2026: Vape - B2C: $19.8 million, B2B: $11.1 million Cannabis - B2C: $3.9 million Launched 180 Smoke V
Retail, Cannabis, Health, Cannabis Dispensary
2026-07-30 7:30 AM EDT | Delota Corp.
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors. Tempra
Technology, Biotechnology, Pharmaceuticals, Health
2026-07-30 7:00 AM EDT | TempraMed Technologies Ltd.
Psyched Wellness Launches Strategic Review to Unlock Shareholder Value
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched Wellness" or the "Company"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, announces that its Board of Directors has commenced a strategic review process designed to evaluate opportunities to enhance and accelerate value creation for shareholders ("Strategic Review").
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-07-29 5:42 PM EDT | Psyched Wellness Ltd.